

(19) World Intellectual Property Organization  
International Bureau







(43) International Publication Date  
14 February 2002 (14.02.2002)

PCT

(10) International Publication Number  
**WO 02/12196 A2**

- (51) International Patent Classification<sup>7</sup>: **C07D 223/00**
- (21) International Application Number: **PCT/US01/22829**
- (22) International Filing Date: **20 July 2001 (20.07.2001)**
- (25) Filing Language: **English**
- (26) Publication Language: **English**
- (30) Priority Data:  
09/633,751 7 August 2000 (07.08.2000) **US**
- (71) Applicant (for all designated States except US): **BRISTOL-MYERS SQUIBB COMPANY** [US/US]; P.O. Box 4000, Route 206 and Provinceline Road, Princeton, NJ 08543-4000 (US).
- (72) Inventors: and
- (75) Inventors/Applicants (for US only): **BISACCHI, Gregory, S.** [US/US]; 130 Mountain Road, Ringoes, NJ 08551 (US). **SEILER, Steven, M.** [US/US]; 101 North Main Street, Pennington, NJ 08534 (US). **LAWRENCE, R., Michael** [US/US]; 48 W. Crown Terrace, Yardley, PA 19067 (US). **SUTTON, James, C., Jr.** [US/US]; 8 Stonelea Drive, Princeton Junction, NJ 08550 (US). **SLUSARCHYK, William, A.** [US/US]; 19 Richmond Drive, Skillman, NJ 08558 (US). **ZHAO, Guohua** [US/US]; 56 York Drive, Princeton, NJ 08540 (US).
- (81) Designated States (national): **AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZW.**
- (84) Designated States (regional): **ARIPO** patent (GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZW), **Eurasian** patent (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), **European** patent (AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR), **OAPI** patent (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG).
- Published:**  
— without international search report and to be republished upon receipt of that report
- For two-letter codes and other abbreviations, refer to the "Guidance Notes on Codes and Abbreviations" appearing at the beginning of each regular issue of the PCT Gazette.

(54) Title: **LACTAM COMPOUNDS AND THEIR USE AS INHIBITORS OF SERINE PROTEASES AND METHOD**




(57) Abstract: Lactam inhibitors are provided which have the structure (I), x is (a) or (b) wherein Y is O or S and R<sup>4</sup> is (i), (ii) or R<sup>8</sup> at least one of R<sup>1</sup> and R<sup>2</sup> is hydrogen, and R<sup>1</sup>, R<sup>2</sup>, R<sup>3</sup>, R<sup>5</sup>, R<sup>6</sup>, R<sup>7</sup>, and R<sup>8</sup>, are as defined herein. These compounds are inhibitors of tryptase and thus are useful in treating asthma. Methods for treating asthma and related diseases are also provided.

WO 02/12196 A2

LACTAM COMPOUNDS AND THEIR USE AS INHIBITORS  
OF SERINE PROTEASES AND METHOD


The present invention relates to lactam inhibitors  
5 of tryptase, which are useful as anti-inflammatory agents  
particularly in the treatment of chronic asthma and  
related diseases.

In accordance with the present invention, novel  
10 substituted lactam derivatives are provided which are  
inhibitors of serine proteases and have the structure I  
I.




including pharmaceutically acceptable salts thereof and  
15 all stereoisomers thereof, and prodrug esters thereof,  
wherein at least one of R<sup>1</sup> and R<sup>2</sup> is hydrogen and the  
other of R<sup>1</sup> and R<sup>2</sup> is selected from hydrogen, alkyl,  
alkenyl, alkynyl, aryl, aminoalkylaryl,  
aminocycloalkylalkyl, aminoalkyl, aminoalkylcycloalkyl,  
20 heteroaryl, arylalkyl, heteroarylalkyl, cycloalkyl,  
cycloalkylalkyl, polycycloalkyl, polycycloalkylalkyl,  
cycloalkenyl, cycloheteroalkyl, cycloalkenylalkyl,  
polycycloalkenyl, polycycloalkenylalkyl, all optionally  
substituted through available carbon atoms with 1, 2, 3  
25 or 4 groups selected from hydrogen, halo, alkyl,  
haloalkyl, alkoxy, haloalkoxy, alkenyl, alkynyl,  
cycloalkyl, cycloalkylalkyl, cycloheteroalkyl,  
cycloheteroalkylalkyl, aryl, heteroaryl, arylalkyl,  
arylcycloalkyl, arylalkenyl, arylalkynyl, aryloxy,  
30 aryloxyalkyl, arylalkoxy, arylazo, heteroarylalkyl,  
heteroarylalkenyl, heteroaryloxy, hydroxy, nitro,

cyano, amino, substituted amino, alkylamino,  
dialkylamino, thiol, alkylthio, arylthio, heteroarylthio,  
arylthioalkyl, aminoalkyl, alkyloxycarbonylaminoalkyl,  
arylalkyloxycarbonylaminoalkyl, alkylcarbonyl,  
5 arylcarbonyl, arylaminocarbonyl, aminocarbonyl,  
alkynylaminocarbonyl, alkylaminocarbonyl,  
alkenylaminocarbonyl, alkylcarbonyloxy, arylcarbonyloxy,  
alkylcarbonylamino, arylcarbonylamino, arylsulfinyl,  
arylsulfinylalkyl, arylsulfonyl, alkylsulfonyl,  
10 arylsulfonylamino, heteroarylcarbonylamino,  
heteroarylsulfinyl, heteroarylthio, heteroarylsulfonyl,  
or alkylsulfinyl;



15




R<sup>3</sup> is selected from alkyl, alkenyl, alkynyl, aryl,  
heteroaryl, arylalkyl, heteroarylalkyl, cycloalkyl,  
cycloalkylalkyl, polycycloalkyl, polycycloalkylalkyl,  
20 cycloalkenyl, cycloheteroalkyl, cycloalkenylalkyl,  
polycycloalkenyl, or polycycloalkenylalkyl; all  
optionally substituted through available carbon atoms  
with 1, 2, 3 or 4 groups selected from hydrogen, halo,  
alkyl, haloalkyl, alkoxy, haloalkoxy, alkenyl, alkynyl,  
25 cycloalkyl, cycloalkylalkyl, cycloheteroalkyl,  
cycloheteroalkylalkyl, aryl, heteroaryl, arylalkyl,  
arylcycloalkyl, arylalkenyl, arylalkynyl, aryloxy,  
aryloxyalkyl, arylalkoxy, arylazo, heteroaryloxy,  
heteroarylalkyl, heteroarylalkenyl, heteroaryloxy,  
30 hydroxy, nitro, cyano, amino, substituted amino,  
alkylamino, dialkylamino, thiol, alkylthio, arylthio,  
heteroarylthio, arylthioalkyl, alkylcarbonyl,  
arylcarbonyl, arylaminocarbonyl, alkoxy carbonyl,

aminocarbonyl, alkynylaminocarbonyl, alkylaminocarbonyl,  
alkenylaminocarbonyl, alkylcarbonyloxy, arylcarbonyloxy,  
alkylcarbonylamino, arylcarbonylamino, arylsulfinyl,  
arylsulfinylalkyl, arylsulfonyl, alkylsulfonyl,  
5 arylsulfonylamino, heteroarylcarbonylamino,  
heteroarylsulfinyl, heteroarylthio, heteroarylsulfonyl,  
or alkylsulfinyl;

R<sup>5</sup> and R<sup>6</sup> are the same or different and are  
independently selected from alkyl, alkenyl, alkynyl,  
10 aryl, heteroaryl, arylalkyl, heteroarylalkyl,  
cycloalkyl, cycloalkylalkyl, polycycloalkyl,  
polycycloalkylalkyl, cycloalkenyl, cycloheteroalkyl,  
cycloalkenylalkyl, polycycloalkenyl,  
polycycloalkenylalkyl, arylcarbonyl, alkylcarbonyl,  
15 alkoxycarbonyl, aryloxycarbonyl, arylsulfonyl, or  
alkylsulfonyl, or R<sup>5</sup> and R<sup>6</sup> can be taken with the  
nitrogen to which they are attached to form a  
cycloheteroalkyl ring; all optionally substituted through  
available carbon atoms with 1, 2, 3 or 4 groups selected  
20 from hydrogen, halo, alkyl, haloalkyl, alkoxy,  
haloalkoxy, alkenyl, alkynyl, cycloalkyl,  
cycloalkylalkyl, cycloheteroalkyl, cycloheteroalkylalkyl,  
aryl, heteroaryl, arylalkyl, arylcycloalkyl, arylalkenyl,  
arylalkynyl, aryloxy, aryloxyalkyl, arylalkoxy, arylazo,  
25 heteroaryloxo, heteroarylalkyl, heteroarylalkenyl,  
heteroaryloxy, hydroxy, nitro, cyano, amino, substituted  
amino, alkylamino, dialkylamino, thiol, alkylthio,  
arylthio, heteroarylthio, arylthioalkyl, alkylcarbonyl,  
arylcarbonyl, arylaminocarbonyl, alkoxycarbonyl,  
30 aminocarbonyl, alkynylaminocarbonyl, alkylaminocarbonyl,  
alkenylaminocarbonyl, alkylcarbonyloxy, arylcarbonyloxy,  
alkylcarbonylamino, arylcarbonylamino, arylsulfinyl,  
arylsulfinylalkyl, arylsulfonyl, alkylsulfonyl,  
arylsulfonylamino, heteroarylcarbonylamino,  
35 heteroarylsulfinyl, heteroarylthio, heteroarylsulfonyl,  
or alkylsulfinyl;

R<sup>7</sup> and R<sup>8</sup> can be the same or different and are independently selected from alkyl, alkenyl, alkynyl, aryl, heteroaryl, arylalkyl, heteroarylalkyl, cycloalkyl, cycloalkylalkyl, polycycloalkyl, polycycloalkylalkyl, cycloalkenyl, cycloheteroalkyl, cycloalkenylalkyl, polycycloalkenyl, polycycloalkenylalkyl, all optionally substituted through available carbon atoms with 1, 2, 3 or 4 groups selected from hydrogen, halo, alkyl, haloalkyl, alkoxy, haloalkoxy, alkenyl, alkynyl, cycloalkyl, cycloalkylalkyl, cycloheteroalkyl, cycloheteroalkylalkyl, aryl, heteroaryl, arylalkyl, arylcycloalkyl, arylalkenyl, arylalkynyl, aryloxy, aryloxyalkyl, arylalkoxy, arylazo, heteroaryloxy, heteroarylalkyl, heteroarylalkenyl, heteroaryloxy, hydroxy, nitro, cyano, amino, substituted amino, alkylamino, dialkylamino, thiol, alkylthio, arylthio, heteroarylthio, arylthioalkyl, alkylcarbonyl, arylcarbonyl, arylaminocarbonyl, alkoxycarbonyl, aminocarbonyl, alkynylaminocarbonyl, alkylaminocarbonyl, alkenylaminocarbonyl, alkylcarbonyloxy, arylcarbonyloxy, alkylcarbonylamino, arylcarbonylamino, arylsulfinyl, arylsulfinylalkyl, arylsulfonyl, alkylsulfonyl, arylsulfonylamino, heteroarylsulfonylamino, heteroarylsulfinyl, heteroarylthio, heteroarylsulfonyl, or alkylsulfinyl.

In preferred embodiments, where in the formula I compounds




and (1) R<sup>1</sup> and R<sup>2</sup> are independently alkyl, cycloalkyl, alkenyl, phenyl, benzyl, cyanoalkyl, alkoxycarbonylalkyl, or phenyl mono- or disubstituted with lower alkyl, cyano, hydroxy, dialkylamino, alkoxy, benzyloxy, alkylamino, alkoxycarbonyl, pyrrolidino, morpholino, halogen, alkyl substituted with one or more fluorines, then Y is S;

and (2) where X is  $\begin{array}{c} \text{R}^4 - \text{C} - \\ \parallel \\ \text{O} \end{array}$  and  $\text{R}^4$  is  $\text{R}^8$ , then  $\text{R}^8$  is other than alkyl substituted with hydroxyaminocarbonyl.


Thus, the compounds of formula I of the invention can have the following structural formulae:

5

IA




IB




10

IC




ID



15

Preferred are compounds of formula ID wherein one of  $\text{R}^1$  and  $\text{R}^2$  is hydrogen and  $\text{Y}$  is  $\text{O}$ .

More preferred are compounds of formula ID wherein  $\text{R}^1$  is  $\text{H}$  and  $\text{R}^2$  is aminoalkylaryl such as



20










and aminocycloalkylalkyl, such as  
is O.















, and y











Preferred compounds of the invention have the  
structures

5









It will be appreciated that in compounds illustrated above and throughout, where a nitrogen is included with an apparent open valence, the nitrogen  
5 includes a hydrogen atom.

In addition, in accordance with the present invention, a method for treating and/or preventing medical conditions related to tryptase (such as asthma, chronic asthma or allergic rhinitis) is provided, wherein  
5 a compound of formula I is administered in a therapeutically effective amount which inhibits tryptase.

The following definitions apply to the terms as used throughout this specification, unless otherwise  
10 limited in specific instances.

Unless otherwise indicated, the term "lower alkyl", "alkyl" or "alk" as employed herein alone or as part of another group includes both straight and branched chain hydrocarbons, containing 1 to 40 carbons (in the  
15 case of alkyl or alk), preferably 1 to 20 carbons, more preferably 1 to 12 carbons (in the case of lower alkyl), in the normal chain, such as methyl, ethyl, propyl, isopropyl, butyl, t-butyl, isobutyl, pentyl, hexyl, isohexyl, heptyl, 4,4-dimethylpentyl, octyl, 2,2,4-  
20 trimethylpentyl, nonyl, decyl, undecyl, dodecyl, the various additional branched chain isomers thereof, and the like as well as such groups including 1 to 4 substituents which may be any of the R<sup>1</sup> or the R<sup>2</sup> substituents set out herein.

25 Unless otherwise indicated, the term "cycloalkyl" as employed herein alone or as part of another group includes saturated or partially unsaturated (containing 1 or 2 double bonds) cyclic hydrocarbon groups containing 1 to 3 rings, including monocyclicalkyl, bicyclicalkyl and  
30 tricyclicalkyl, containing a total of 3 to 20 carbons forming the rings, preferably 4 to 12 carbons, forming the ring and which may be fused to one aromatic ring as described for aryl, which include cyclopropyl,

cyclobutyl, cyclopentyl, cyclohexyl, cycloheptyl,  
cyclooctyl, cyclodecyl and cyclododecyl, cyclohexenyl,



5 any of which groups may be optionally substituted with 1  
to 4 substituents which may be any of the R<sup>1</sup> groups, or  
the R<sup>1</sup> substituents set out herein.

The term "cycloalkenyl" as employed herein alone  
or as part of another group refers to cyclic hydrocarbons  
10 containing 5 to 20 carbons, preferably 6 to 12 carbons  
and 1 or 2 double bonds. Exemplary cycloalkenyl groups  
include cyclopentenyl, cyclohexenyl, cycloheptenyl,  
cyclooctenyl, cyclohexadienyl, and cycloheptadienyl,  
which may be optionally substituted as defined for  
15 cycloalkyl.

The term "aryl" as employed herein alone or as  
part of another group refers to monocyclic and bicyclic  
aromatic groups containing 6 to 10 carbons in the ring  
portion (such as phenyl or naphthyl including 1-naphthyl  
20 and 2-naphthyl) and may optionally include one to three  
additional rings fused to a carbocyclic ring or a  
heterocyclic ring (such as aryl, cycloalkyl, heteroaryl  
or cycloheteroalkyl rings) and may be optionally  
substituted through available carbon atoms with 1, 2, or  
25 3 groups selected from hydrogen, halo, haloalkyl, alkyl,  
haloalkyl, alkoxy, haloalkoxy, alkenyl, trifluoromethyl,  
trifluoromethoxy, alkynyl, cycloalkylalkyl, cycloalkyl,  
cycloheteroalkyl, cycloheteroalkylalkyl, aryl,  
aminoalkyl, heteroaryl, arylalkyl, aryloxy, aryloxyalkyl,  
30 arylalkoxy, arylthio, arylazo, heteroarylalkyl,  
heteroarylalkenyl, heteroarylheteroaryl, heteroaryloxy,  
hydroxy, nitro, cyano, amino, substituted amino wherein  
the amino includes 1 or 2 substituents (which are alkyl,  
aryl or any of the other aryl compounds mentioned in the  
35 definitions), thiol, alkylthio, arylthio, heteroarylthio,

arylthioalkyl, alkoxyarylthio, alkylcarbonyl,  
arylcarbonyl, alkyl-aminocarbonyl, arylaminocarbonyl,  
alkoxycarbonyl, aminocarbonyl, alkylcarbonyloxy,  
arylcarbonyloxy, alkylcarbonylamino, arylcarbonylamino,  
5 arylsulfinyl, arylsulfinylalkyl, arylsulfonylamino or  
arylsulfon-aminocarbonyl or any of the R<sup>1</sup> groups or the  
R<sup>1</sup> substituents set out herein.

The term "aralkyl", "aryl-alkyl" or "aryllower  
alkyl" as used herein alone or as part of another group  
10 refers to alkyl groups as discussed above having an aryl  
substituent, such as benzyl or phenethyl, or  
naphthylpropyl, or an aryl as defined above.

The term "lower alkoxy", "alkoxy", "aryloxy" or  
"aralkoxy" as employed herein alone or as part of another  
15 group includes any of the above alkyl, aralkyl or aryl  
groups linked to an oxygen atom.

The term "amino" as employed herein alone or as part  
of another group may optionally be independently  
substituted with one or two substituents, which may be  
20 the same or different, such as alkyl, aryl, arylalkyl,  
heteroaryl, heteroarylalkyl, cycloheteroalkyl,  
cycloheteroalkylalkyl, cycloalkyl, cycloalkylalkyl,  
haloalkyl, hydroxyalkyl, alkoxyalkyl or thioalkyl. These  
substituents may be further substituted with a carboxylic  
25 acid or any of the R<sup>1</sup> groups or R<sup>1</sup> substituents thereof  
as set out above. In addition, the amino substituents  
may be taken together with the nitrogen atom to which  
they are attached to form 1-pyrrolidinyl, 1-piperidinyl,  
1-azepinyl, 4-morpholinyl, 4-thiamorpholinyl, 1-  
30 piperazinyl, 4-alkyl-1-piperazinyl, 4-arylalkyl-1-  
piperazinyl, 4-diarylalkyl-1-piperazinyl, 1-pyrrolidinyl,  
1-piperidinyl, or 1-azepinyl, optionally substituted with  
alkyl, alkoxy, alkylthio, halo, trifluoromethyl or  
hydroxy.

35 The term "lower alkylthio", "alkylthio", "arylthio"  
or "aralkylthio" as employed herein alone or as part of

another group includes any of the above alkyl, aralkyl or aryl groups linked to a sulfur atom.

5 The term "lower alkylamino", "alkylamino", "arylamino", or "arylalkylamino" as employed herein alone or as part of another group includes any of the above alkyl, aryl or arylalkyl groups linked to a nitrogen atom.

The term "acyl" as employed herein by itself or part of another group, as defined herein, refers to an  
10 organic radical linked to a carbonyl  $\begin{pmatrix} \text{O} \\ \parallel \\ \text{C} \end{pmatrix}$  group; examples of acyl groups include any of the R<sup>1</sup> groups attached to a carbonyl, such as alkanoyl, alkenoyl, aroyl, aralkanoyl, heteroaroyl, cycloalkanoyl, cycloheteroalkanoyl and the like.

15 The term "alkanoyl" as used herein alone or as part of another group refers to alkyl linked to a carbonyl group.

Unless otherwise indicated, the term "lower alkenyl" or "alkenyl" as used herein by itself or as part  
20 of another group refers to straight or branched chain radicals of 2 to 20 carbons, preferably 3 to 12 carbons, and more preferably 1 to 8 carbons in the normal chain, which include one to six double bonds in the normal chain, such as vinyl, 2-propenyl, 3-butenyl, 2-butenyl,  
25 4-pentenyl, 3-pentenyl, 2-hexenyl, 3-hexenyl, 2-heptenyl, 3-heptenyl, 4-heptenyl, 3-octenyl, 3-nonenyl, 4-decenyl, 3-undecenyl, 4-dodecenyl, 4,8,12-tetradecatrienyl, and the like, and which may be optionally substituted with 1 to 4 substituents, namely, halogen, haloalkyl, alkyl,  
30 alkoxy, alkenyl, alkynyl, aryl, arylalkyl, cycloalkyl, amino, hydroxy, heteroaryl, cycloheteroalkyl, alkanoylamino, alkylamido, arylcarbonyl-amino, nitro, cyano, thiol, alkylthio or any of the R<sup>1</sup> groups, or the R<sup>1</sup> substituents set out herein.

35 Unless otherwise indicated, the term "lower alkynyl" or "alkynyl" as used herein by itself or as part of another group refers to straight or branched chain



radicals of 2 to 20 carbons, preferably 2 to 12 carbons and more preferably 2 to 8 carbons in the normal chain, which include one triple bond in the normal chain, such as 2-propynyl, 3-butynyl, 2-butynyl, 4-pentynyl, 3-pentynyl, 2-hexynyl, 3-hexynyl, 2-heptynyl, 3-heptynyl, 4-heptynyl, 3-octynyl, 3-nonyl, 4-decynyl, 3-undecynyl, 4-dodecynyl and the like, and which may be optionally substituted with 1 to 4 substituents, namely, halogen, haloalkyl, alkyl, alkoxy, alkenyl, alkynyl, aryl, arylalkyl, cycloalkyl, amino, heteroaryl, cycloheteroalkyl, hydroxy, alkanoylamino, alkylamido, arylcarbonylamino, nitro, cyano, thiol, and/or alkylthio, or any of the R<sup>1</sup> groups, or the R<sup>1</sup> substituents set out herein.







Where alkyl groups as defined above have single bonds for attachment to other groups at two different carbon atoms, they are termed "alkylene" groups and may optionally be substituted as defined above for "alkyl".

Where alkenyl groups as defined above and alkynyl groups as defined above, respectively, have single bonds for attachment at two different carbon atoms, they are termed "alkenylene groups" and "alkynylene groups", respectively, and may optionally be substituted as defined above for "alkenyl" and "alkynyl".

Suitable alkylene, alkenylene or alkynylene groups (CH<sub>2</sub>)<sub>p</sub> (where, p is 1 to 8, preferably 1 to 5) (which may include alkylene, alkenylene or alkynylene groups) as defined herein, may optionally include 1, 2, or 3 substituents which include any of the R<sup>1</sup> groups, or the R<sup>1</sup> substituents set out herein.

Examples of alkylene, alkenylene and alkynylene include






20 The term "halogen" or "halo" as used herein alone or as part of another group refers to chlorine, bromine, fluorine, and iodine as well as CF<sub>3</sub>, with chlorine or fluorine being preferred.

The term "metal ion" refers to alkali metal ions such as sodium, potassium or lithium and alkaline earth metal ions such as magnesium and calcium, as well as zinc and aluminum.

25 The term "cycloheteroalkyl" as used herein alone or as part of another group refers to a 5-, 6- or 7-


membered saturated or partially unsaturated ring which includes 1 to 2 hetero atoms such as nitrogen, oxygen and/or sulfur; linked through a carbon atom or a heteroatom, where possible, optionally via the linker (CH<sub>2</sub>)<sub>p</sub> (which is defined above), such as




10

and the like. The above groups may include 1 to 4 substituents such as alkyl, halo, oxo and/or any of the R<sup>1</sup> groups, or the R<sup>1</sup> substituents set out herein. In addition, any of the above rings can be fused to a cycloalkyl, aryl, heteroaryl or cycloheteroalkyl ring.

The term "heteroaryl" as used herein alone or as part of another group refers to a 5- or 6- membered aromatic ring which includes 1, 2, 3 or 4 hetero atoms such as nitrogen, oxygen or sulfur, and such rings fused to an aryl, cycloalkyl, heteroaryl or cycloheteroalkyl ring (e.g. benzothiophenyl, indolyl), and includes possible N-oxides. The heteroaryl group may optionally include 1 to 4 substituents such as any of the R<sup>1</sup> groups or the R<sup>1</sup> substituents set out above. Examples of heteroaryl groups include the following:







5

and the like.

The term "cycloheteroalkylalkyl" as used herein alone or as part of another group refers to  
 10 cycloheteroalkyl groups as defined above linked through a C atom or heteroatom to a  $(CH_2)_p$  chain.

The term "heteroarylalkyl" or "heteroarylalkenyl" as used herein alone or as part of another group refers to a heteroaryl group as defined above linked through a C  
 15 atom or heteroatom to a  $-(CH_2)_p-$  chain, alkylene or alkenylene as defined above.

The term "polyhaloalkyl" as used herein refers to an "alkyl" group as defined above which includes from 2  
 20 to 9, preferably from 2 to 5, halo substituents, such as F or Cl, preferably F, such as  $CF_3CH_2$ ,  $CF_3$  or  $CF_3CF_2CH_2$ .

The term "polyhaloalkyloxy" as used herein refers to an "alkoxy" or "alkyloxy" group as defined above which includes from 2 to 9, preferably from 2 to 5, halo  
 25 substituents, such as F or Cl, preferably F, such as  $CF_3CH_2O$ ,  $CF_3O$  or  $CF_3CF_2CH_2O$ .

The compounds of formula I can be present as salts, in particular pharmaceutically acceptable salts. If the compounds of formula I have, for example, at least one basic center, they can form acid addition salts. These are formed, for example, with strong inorganic acids, such as mineral acids, for example sulfuric acid, phosphoric acid or a hydrohalic acid, with strong organic carboxylic acids, such as alkanecarboxylic acids of 1 to 4 carbon atoms which are unsubstituted or substituted, for example, by halogen, for example acetic acid, such as saturated or unsaturated dicarboxylic acids, for example oxalic, malonic, succinic, maleic, fumaric, phthalic or terephthalic acid, such as hydroxycarboxylic acids, for example ascorbic, glycolic, lactic, malic, tartaric or citric acid, such as amino acids, (for example aspartic or glutamic acid or lysine or arginine), or benzoic acid, or with organic sulfonic acids, such as (C<sub>1</sub>-C<sub>4</sub>)-alkyl- or aryl-sulfonic acids which are unsubstituted or substituted, for example by halogen, for example methane- or p-toluene-sulfonic acid. Corresponding acid addition salts can also be formed having, if desired, an additionally present basic center. The compounds of formula I having at least one acid group (for example COOH) can also form salts with bases. Suitable salts with bases are, for example, metal salts, such as alkali metal or alkaline earth metal salts, for example sodium, potassium or magnesium salts, or salts with ammonia or an organic amine, such as morpholine, thiomorpholine, piperidine, pyrrolidine, a mono-, di- or tri-lower alkylamine, for example ethyl-, tert-butyl-, diethyl-, diisopropyl-, triethyl-, tributyl- or dimethyl-propylamine, or a mono-, di- or trihydroxy lower alkylamine, for example mono-, di- or triethanolamine. Corresponding internal salts may furthermore be formed. Salts which are unsuitable for pharmaceutical uses but which can be employed, for example, for the isolation or

purification of free compounds I or their pharmaceutically acceptable salts, are also included.

Preferred salts of the compounds of formula I include monohydrochloride, hydrogensulfate, methanesulfonate, phosphate or nitrate.

All stereoisomers of the compounds of the instant invention are contemplated, either in admixture or in pure or substantially pure form. The compounds of the present invention can have asymmetric centers at any of the carbon atoms including any one of the R substituents. Consequently, compounds of formula I can exist in enantiomeric or diastereomeric forms or in mixtures thereof. The processes for preparation can utilize racemates, enantiomers or diastereomers as starting materials. When enantiomeric or diastereomeric products are prepared, they can be separated by conventional methods for example, chromatographic or fractional crystallization.


It should be understood that the present invention includes prodrug forms of the compounds of formula I such as alkylesters of acids or any known prodrugs for lactam derivatives.

The compounds of the instant invention may, for example, be in the free or hydrate form, and may be obtained by methods exemplified by the following descriptions.

The compounds of formula I may be prepared by the exemplary processes described in the following reaction schemes. Exemplary reagents and procedures for these reactions appear hereinafter and in the working Examples.

Compounds of formula I of the invention can be prepared from the corresponding amine 1 by using the sequence of steps outlined in Scheme I set out below.

## Reaction Scheme I



10

Reaction of amine 1 in an inert organic solvent such as dichloromethane, chloroform or tetrahydrofuran with reactant acid chloride 2, sulfonyl chloride 3, chloroformate 4 or carbamoylchloride 5, employing a molar ratio of reactant:amine 1 within the range from about 5:1 to about 1:5, optionally in the presence of an acid scavenger such as triethylamine, diisopropylethylamine,

5

### Reaction Scheme 1A




15

X is  $\begin{array}{c} R^4-C- \\ || \\ Y \end{array}$ , Y is O and R<sup>4</sup> is  $\begin{array}{c} R^5 \\ \diagdown \\ N- \\ \diagup \\ R^6 \end{array}$

20

## Reaction Scheme II



5 Procedure A: For amines where  $\text{R}^1$  or  $\text{R}^2$  contain additional basic nitrogens.

Procedure B: For amines where  $\text{R}^1$  or  $\text{R}^2$  contain no additional basic nitrogens.

10 In Procedure A (for amines where  $\text{R}^1$  or  $\text{R}^2$  contain additional basic nitrogens), a mixture of a solution of amine 21 in an inert organic solvent such as THF, methylenechloride or chloroform, a carbodiimide such as diisopropylcarbodiimide (DIC) and 7-aza-1-hydroxy-  
 15 benzotriazole (HOAt) is reacted with acid 20, employing a molar ratio of amine 21:acid 20 within the range from about 5:1 to about 1:5, preferably at about 1:1.1, to form a reaction mixture which is purified via an SCX column to separate out compound IB of the invention.

20 The DIC will be employed in a molar ratio to acid 20 within the range from about 5:1 to about 1:5, preferably at about 1.6:1, and the HOAt will be employed in a molar ratio acid 20 within the range from about 5:1 to about 1:5, preferably at about 1.6:1.

25 In Procedure B (for amines where  $\text{R}^1$  and/or  $\text{R}^2$  contain no additional basic nitrogens) a mixture of a solution of amine 21 in an inert organic solvent such as THF, methylenechloride or chloroform, ethyldimethylaminopropylcarbodiimide (EDAC) and  
 30 dimethylaminopyridine (DMAP) with acid 20, employing a molar ratio of amine 21:acid 20 within the range from about 5:1 to about 1:5, preferably at about 1.5:1, to


form a reaction mixture which is purified via a SCX column to separate out compound IB of the invention.

The EDAC will be employed in a molar ratio to acid 20 within the range from about 5:1 to about 1.5, preferably at about 1.5:1, and the DMAP will be employed in a molar ratio to acid 20 within the range from about 5:1 to about 1:5, preferably at about 1.5:1.

Starting compound 20 can be prepared by methods known in the art as outlined in Reaction Scheme IIA.


10

#### Reaction Scheme IIA




20

Compounds of formula I of the invention wherein



can be prepared from the corresponding amine 1 by using  
 5 the sequence of steps outlined in Scheme III set out  
 below.


### Reaction Scheme III



10


Reaction of amine 1 (in an inert organic solvent  
 such as dichloromethane, chloroform or tetrahydrofuran)  
 with reactant 30 or 31 employing a molar ratio of 30 or  
 15 31:amine 1 within the range of from about 5:1 to about  
 1:5, followed by treatment with aminomethylpolystyrene  
 (32), affords the compound of the invention IB' or IB''.

Compounds of formula I of the invention wherein



can be prepared from the corresponding acid 29






29

5 using the sequence of steps outlined in Scheme IV set out below:


#### Reaction Scheme IV




15  $\text{R}^1$  and/or  $\text{R}^2$  can be neutral or may contain a basic nitrogen. When  $\text{R}^1$  or  $\text{R}^2$  contains a basic nitrogen, the nitrogen may optionally be protected, for example with a BOC group or Cbz group. The protecting group can then be removed, for example, by treating with TFA in methylene chloride for removal of a BOC or Cbz protecting group.

Starting compound 29 can be prepared by methods as outlined in Reaction Scheme IVa


## Reaction Scheme IVa



5 Alternatively, compounds of formula I of the invention wherein




can be prepared from the corresponding amine **1**




15 using the sequence of steps outline in Scheme V set out below.

# Reaction Scheme V:



- 5  $R^1$  and/or  $R^2$  can be neutral or may contain a basic nitrogen. When  $R^1$  or  $R^2$  in starting amine 1 contains a basic nitrogen, the nitrogen may optionally be protected, for example, with a BOC group. The protecting group can then be removed, for example, by treating with TFA in
- 10 methylene chloride for removal of a BOC protecting group, as outlined below in Reaction Scheme VA.

## Reaction Scheme VA



15

- The novel compounds of formula I of the invention possess tryptase inhibition activity. This activity was confirmed using either isolated human skin tryptase or
- 20 recombinant human tryptase prepared from the human

recombinant beta-protryptase expressed by baculovirus in insect cells. The expressed beta-protryptase was purified using sequential immobilized heparin affinity resin followed by an immunoaffinity column using an anti-tryptase monoclonal antibody. The protryptase was activated by auto-catalytic removal of the N-terminal in the presence of dextran sulfate followed by dipeptidyl peptidase I (DPPI) removal of the two N-terminal amino acids to give the mature active enzyme (Sakai et al, J. Clin. Invest., 97, pages 988-995, 1996). Essentially equivalent results were obtained using isolated native enzyme or the activated expressed enzyme. The tryptase enzyme was maintained in 2M sodium chloride, 10 mM 4-morpholine-propanesulfonic acid, pH 6.8.

The assay procedure employed a 96 well microplate. To each well of the microplate (Nunc MaxiSorp), 250  $\mu$ l of assay buffer [containing low molecular weight heparin and tris (hydroxymethyl)aminomethane] was added followed by 2.0  $\mu$ l of the test compound in dimethylsulfoxide. The substrate (10  $\mu$ l) was then added to each well to give a final concentration of either 370  $\mu$ M benzoyl-arginine-p-nitroaniline (BAPNA) or 100  $\mu$ M benzyloxycarbonyl-glycine-proline-arginine-p-nitroaniline (CBz-Gly-Pro-Arg-pNA). Similar data was obtained using either substrate. The microplate was then shaken on a platform vortex mixer at a setting of 800 (Sarstedt TPM-2). After a total of three minutes incubation, 10  $\mu$ l of the working stock solution of tryptase (6.1 mM final tryptase concentration for use with BAPNA or 0.74 nM for use with CBz-Gly-Pro-Arg-pNA) was added to each well. The microplate was vortexed again for one minute and then incubated without shaking at room temperature for an additional 2 minutes. After this time the microplate was read on a microplate reader (Molecular Devices UV max) in the kinetic mode (405 nm wavelength) over twenty minutes at room temperature. To determine the compound concentration that inhibited half of the enzyme activity ( $IC_{50}$ ), the

fraction of control activity (FCA) was plotted as a function of the inhibitor concentration and curve to fit  $FCA/(1[I]/IC_{50})$ . The  $IC_{50}$  for each compound was determined 2-4 times and the obtained values were averaged.

5 As a result of this tryptase activity, the compounds of formula I as well as a pharmaceutically acceptable salt thereof, are useful as anti-inflammatory agents particularly in the treatment and/or prevention of chronic asthma and may also be useful in treating and/or  
10 preventing allergic rhinitis, inflammatory bowel disease, psoriasis, conjunctivitis, atopic dermatitis, rheumatoid arthritis, osteoarthritis, and other chronic inflammatory joint diseases, or diseases of joint cartilage destruction. Additionally, these compounds may be useful  
15 in treating or preventing myocardial infarction, stroke, angina and other consequences of atherosclerotic plaque rupture. Additionally, these compounds may be useful for treating or preventing diabetic retinopathy, tumor growth and other consequences of angiogenesis. Additionally,  
20 these compounds may be useful for treating or preventing fibrotic conditions, for example, fibrosis, scleroderma, pulmonary fibrosis, liver cirrhosis, myocardial fibrosis, neurofibromas and hypertrophic scars. Additionally these compounds may be useful for treating and/or preventing  
25 diseases involving angiogenesis including, but not limited to, cancer.

The compounds of the present invention may be used in combination with  $\beta$ -adrenergic agonists such as albuterol, terbutaline, formoterol, salmeterol,  
30 bitolterol, pilbuterol, or fenoterol, as well as with anticholinergics such as ipratropium bromide, anti-inflammatory corticosteroids such as beclomethasone, triamcinolone, budesonide, fluticasone, flunisolide or dexamethasone, and anti-inflammatory agents such as  
35 cromolyn, nedocromil, theophylline, zileuton, zafirlukast, monteleukast and pranleukast, and/or hypolipodemic agents such as pravastatin, simvastatin,

atorvastatin, fluvastatin, cerivastatin, itavastatin  
(pitavastatin, NK-104), or visastatin (or rosuvastatin).

The compounds of the invention can be administered orally or parenterally such as subcutaneously or  
5 intravenously, as well as by inhalation and nasal application, rectally, transdermally, or sublingually to various mammalian species known to be subject to such maladies, e.g., humans, cats, dogs and the like in an effective amount within the dosage range of about 0.1 to  
10 about 100 mg/kg, preferably about 0.2 to about 50 mg/kg and more preferably about 0.5 to about 25 mg/kg (or from about 1 to about 2500 mg, preferably from about 5 to about 2000 mg) on a regimen in single or 2 to 4 divided daily doses.

15 The active substance can be utilized in a composition such as tablet, capsule, solution or suspension or in other type carrier materials such as transdermal devices, iontophoretic devices, rectal suppositories, inhalant devices and the like. The  
20 composition or carrier will contain about 5 to about 500 mg per unit of dosage of a compound or mixture of compounds of formulas I, IA., IB, IC and ID. They may be compounded in conventional matter with a physiologically acceptable vehicle or carrier, excipient, binder,  
25 preservative, stabilizer, flavor, etc., as called for by accepted pharmaceutical practice.

The following abbreviations are employed hereinbefore and in the Examples:

30 Ph = phenyl  
Bn = benzyl  
t-Bu = tertiary butyl  
Me = methyl  
35 Et = ethyl  
TMS = trimethylsilyl  
TMSN<sub>3</sub> = trimethylsilyl azide  
TBS = tert-butyldimethylsilyl  
Fmoc = fluorenylmethoxycarbonyl  
40 Boc = tert-butoxycarbonyl  
Cbz = carbobenzyloxy or carbobenzoyloxy or benzyloxycarbonyl  
THF = tetrahydrofuran

Et<sub>2</sub>O = diethyl ether  
 hex = hexanes  
 EtOAc = ethyl acetate  
 DMF = dimethyl formamide  
 5 MeOH = methanol  
 EtOH = ethanol  
 i-PrOH = isopropanol  
 DMSO = dimethyl sulfoxide  
 DME = 1,2 dimethoxyethane  
 10 EDC or DCE = 1,2 dichloroethane  
 HMPA = hexamethyl phosphoric triamide  
 HOAc or AcOH = acetic acid  
 TFA = trifluoroacetic acid  
 i-Pr<sub>2</sub>NEt = diisopropylethylamine  
 15 Et<sub>3</sub>N = triethylamine  
 NMM = N-methyl morpholine  
 DMAP = 4-dimethylaminopyridine  
 NaBH<sub>4</sub> = sodium borohydride  
~~NaBH(OAc)<sub>3</sub> = sodium triacetoxymborohydride~~  
 20 DIBALH = diisobutyl aluminum hydride  
 DCM = 4-(dicyanomethylene)-2-methyl-6-(4-dimethylamino-  
 styryl)-4H-pyran  
 LiAlH<sub>4</sub> = lithium aluminum hydride  
 n-BuLi = n-butyllithium  
 25 Pd/C = palladium on carbon  
 PtO<sub>2</sub> = platinum oxide  
 KOH = potassium hydroxide  
 NaOH = sodium hydroxide  
 LiOH = lithium hydroxide  
 30 K<sub>2</sub>CO<sub>3</sub> = potassium carbonate  
 NaHCO<sub>3</sub> = sodium bicarbonate  
 DBU = 1,8-diazabicyclo[5.4.0]undec-7-ene  
 EDC (or EDC.HCl) or EDCI (or EDCI.HCl) or EDAC = 3-ethyl-  
 3'-(dimethylamino)propyl- carbodiimide hydrochloride (or  
 35 1-(3-dimethylaminopropyl)-3-ethylcarbodiimide  
 hydrochloride)  
 HOBT or HOBT.H<sub>2</sub>O = 1-hydroxybenzotriazole hydrate  
 HOAT = 1-Hydroxy-7-azabenzotriazole  
 BOP reagent = benzotriazol-1-yloxy-tris (dimethylamino)  
 40 phosphonium hexafluorophosphate  
 NaN(TMS)<sub>2</sub> = sodium hexamethyldisilazide or sodium  
 bis(trimethylsilyl)amide  
 Ph<sub>3</sub>P = triphenylphosphine  
 Pd(OAc)<sub>2</sub> = Palladium acetate  
 45 (Ph<sub>3</sub>P)<sub>4</sub>Pd<sup>0</sup> = tetrakis triphenylphosphine palladium  
 DEAD = diethyl azodicarboxylate  
 DIAD = diisopropyl azodicarboxylate  
 Cbz-Cl = benzyl chloroformate  
 CAN = ceric ammonium nitrate  
 50 SAX = Strong Anion Exchanger  
 SCX = Strong Cation Exchanger  
 Ar = argon


- N<sub>2</sub> = nitrogen  
min = minute(s)  
h or hr = hour(s)  
L = liter
- 5 mL = milliliter  
μL = microliter  
g = gram(s)  
mg = milligram(s)  
mol = moles
- 10 mmol = millimole(s)  
meq = milliequivalent  
RT = room temperature  
sat or sat'd = saturated  
aq. = aqueous
- 15 TLC = thin layer chromatography  
HPLC = high performance liquid chromatography  
LC/MS = high performance liquid chromatography/mass  
spectrometry  
MS or Mass Spec = mass spectrometry
- 20 NMR = nuclear magnetic resonance  
mp = melting point




The following working Examples represent preferred embodiments of the present invention.

5


Example 1



A.




10




To a solution of (16.77 g, 73.6 mmol, 1.0 eq) in THF (400 mL) under a nitrogen atmosphere at  
15 -78°C was added LiHMDS (1.0 M in THF, 150 mL, 150 mmol, 2.04 eq) dropwise via an addition funnel over 10 minutes. The resulting mixture was stirred for an additional 10 minutes at -78°C, warmed to room temperature and stirred at room temperature for 1 hour. The reaction mixture was  
20 then cooled to -78°C and phenyl 2-bromoacetate (14 mL, 88.3 mmol, 1.2 eq) was added. The reaction mixture was warmed to room temperature and stirred for 18 hours. 1N KHSO<sub>4</sub> was added until the pH remained neutral. NaCl (~5 g) was added to the resulting bi-phasic solution. After  
25 the layers were mixed and allowed to separate, the upper THF layer was removed and set aside and the aqueous layer was extracted once with EtOAc. The combined THF and EtOAc extracts were dried over MgSO<sub>4</sub>, filtered and concentrated. Purification by silica gel chromatography  
30 provided 21g of title compound (75.7%). MS: m/z 399 (M + Na)<sup>+</sup>.

B.




A solution of Part A compound (7.0 g, 18.59 mmol, 1.0 eq) in 4 M HCl in dioxane (25 mL) was stirred at room temperature for 1.5 hours. Solvents were removed and the residue was reconstituted in  $\text{CH}_2\text{Cl}_2/\text{Et}_2\text{O}$  to give 6.0 g of an off-white precipitate. Re-crystallization from  $\text{CH}_2\text{Cl}_2/\text{Et}_2\text{O}$  afforded 5.14 g (88%) of title compound as a white solid. MS:  $m/z$  277 ( $\text{M} + \text{H}$ )<sup>+</sup>.

C.



A solution of Part B compound (2.7 g, 8.63 mmol, 1 eq), EDC (1.98 g, 10.3 mmol, 1.2 eq), HOBT (1.40 g, 10.35 mmol, 1.2 eq) in  $\text{CH}_2\text{Cl}_2$  (100 mL) at 0°C was treated with  $i\text{Pr}_2\text{NEt}$  (6.0 mL, 34.5 mmol, 4 eq). The reaction mixture was brought to room temperature and 4-biphenylcarboxylic acid (2.05 g, 10.35 mmol, 1.2 eq) was added. The reaction mixture was stirred at room temperature for 3 hours. The reaction mixture was then diluted with  $\text{CH}_2\text{Cl}_2$ , washed with 5%  $\text{NaHCO}_3$ , dried over  $\text{MgSO}_4$ , filtered and concentrated. Purification by silica gel chromatography gave 2.16g (55%) of title compound as a white foam. MS:  $m/z$  479 ( $\text{M} + \text{Na}$ )<sup>+</sup>.


D.



To a solution of Part C compound (4.5 g, 9.86 mmol, 1.0 eq) in THF (200 mL) at RT was added 10%Pd/C (3 g) followed by bubbling of H<sub>2</sub> through the solution for 1 hour. The reaction was then stirred under H<sub>2</sub> for 4 hours. The reaction mixture was filtered through a pad of celite and the pad was rinsed twice with THF (2x25 mL). Solvent was removed to provide 3.62 g (100%) of title compound as a white solid. MS: m/z 367 (M + H)<sup>+</sup>.

10

E.




Part E compound was prepared as part of a semi-automated parallel library.

15

To a 16x100 mm reaction tube was added Part D compound (30 mg, 0.082 mmol, 1.0 eq), polystyrene-EDC (Advanced Chemtech catalog #SP5005, 100 mg, 0.8 mmol/g, 0.08 mmol, 0.98 eq), iPr<sub>2</sub>NEt (0.05 mL, 0.29 mmol, 3.5 eq)

20


and amine  (14 mg, 0.063 mmol, 0.77 eq) in DMF (0.6 mL) and DCE (1.0 mL), and was shaken for 3 days. Additional polystyrene-EDC (50 mg, 0.8 mmol/g, 0.04 mmol, 0.49 eq) and DCE (0.5 mL) were added and the reaction mixture was shaken for an additional 24 hours. To the reaction mixture was added Polystyrene-Trisamine

25

(Argonaut Tech, 50 mg, 6.8 mmol/g, 0.34 mmol, 4.15 eq) as a scavenger resin and the reaction mixture was shaken for 24 hours. The reaction mixture was filtered and the eluent was concentrated using a speed vac. Purification by reverse phase preparative HPLC (Shimadzu VP-ODS, flow rate 20 mL/min) followed by concentration using a speed vac gave analytically pure title compound. MS: m/z 593 (M+Na)<sup>+</sup>.


30

F.



For compounds from the above semi-automated  
 5 parallel library having BOC protecting groups,  
 deprotection was carried out using the following  
 procedure.

Part E compound was taken up in 10% TFA in DCE (5  
 mL) and let set for 2 hours. Concentration using a speed  
 10 vac then afforded 4.8 mg (10% from Part D compound) of  
 title compound. MS: m/z 471 (M + H)<sup>+</sup>.


Example 2

A.




20 The title compound is a known compound as disclosed  
 in Skiles, J.W., et al, Bioorg. Med. Chem. Lett., 1993,  
 3, 773.

B.

3-Boc-aminomethyl aniline


The title compound is a known compound as disclosed  
 in Collins, J.L., et al, J. Med. Chem., 1998, 41, 2858.

C.



5 TFA (20 mL) was slowly added to a solution of Part A compound (8.64 g, 22.95 mmol) in CH<sub>2</sub>Cl<sub>2</sub> (30 mL) at 0°C. The reaction mixture was then stirred at room temp. After 24 h the solution was concentrated. The residue was dissolved in CHCl<sub>3</sub> (50 mL) and the solution was concentrated. This was repeated 2 more times. A portion  
10 of the crude product was purified by silica gel chromatography giving 2.90 g of title compound.


D.



15

EDAC-HCl (1.74 g, 9.05 mmol) was added to a stirred solution of Part B compound (2.01g, 9.05 mmol), Part C compound (2.90 g, 9.05 mmol) and HOBT (1.22 g, 9.05 mmol) in CH<sub>2</sub>Cl<sub>2</sub> (35 mL) at 0°C. NMM (1.04 mL, 9.50 mmol) was  
20 added and the reaction mixture was stirred at room temp. After 24 h the solution was diluted with CH<sub>2</sub>Cl<sub>2</sub> (100 mL) and washed with 5% KHSO<sub>4</sub> (50 mL), sat. NaHCO<sub>3</sub> (50 mL), and sat NaCl (50 mL). The solution was dried (MgSO<sub>4</sub>) and concentrated. The crude product was purified by silica  
25 gel chromatography to afford 3.60 g (78%) of title compound.


E.




30

20% Pd(OH)<sub>2</sub> (0.34 g) was added to a stirred solution of Part D compound (3.39g, 6.65 mmol) in MeOH (25 mL). A H<sub>2</sub> atmosphere was introduced via balloon. After 24 h the solution was filtered and the filtrate was  
35 concentrated to give 2.44 g (94%) of title compound.


F.



5 To a reaction tube was added via liquid handler 320  $\mu$ L (10.8 mg, 0.048 mmol) of a 0.15 M stock solution of



in DMF. 0.30 mL of a DCE solution containing EDC (10.5 mg, 0.055 mmol) and DMAP (6.7 mg, 0.055 mmol) was added manually via syringe. 0.30 mL of a DCE solution containing Part E compound (18.8 mg, 0.050 mmol) was added via the liquid handler. The reaction tube was mixed on an orbital shaker for 12 h. The reaction mixture was then drained through a SCX cation exchange column (0.30 g of absorbent) which was preconditioned with MeOH (0.30 mL) into a 2.5 mL microtube. The column was rinsed with  $\text{CH}_2\text{Cl}_2$  (0.30 mL) and MeOH (0.40 mL). The organic solution containing intermediate F(1)




was concentrated by speed vac.

DCE (0.60 mL) was added to the 2.5 mL microtube containing the above intermediate F(1). Upon dissolution TFA (0.30 mL) was added via syringe. The microtube was sealed and shaken using a mini-vortexer. After 3 h the solution was concentrated by speed vac. The product was dissolved in MeOH (1.0 mL) and purified via solid phase extraction using a SCX cation exchange column (0.30 g of absorbent) which was preconditioned with MeOH (0.30 mL). The column was washed with MeOH (2 x 1.5 mL) to remove impurities. The product was then eluted off the column using 2.0 M  $\text{NH}_3$  in MeOH (1.5 mL). The eluant was then concentrated by speed vac. The crude product was further purified by PREP HPLC (Shimadzu VP-ODS 20 x 50 mm column) using a gradient of 0 to 100% Solvent B over 5 min and a

flow rate of 20 mL/min. 6.73 mg (23%) of title compound was obtained. Mass spec  $(M+H)^+ = \text{calc'd} = 499$ , found = 499.

5

### Example 3



Solution A: To a solution of Example 1 Part D compound (240 mg, 0.655 mmol) in dichloroethane (15 ml) was added DMAP (199 mg, 1.63 mmol) followed by EDC (251 mg, 1.31 mmol). Dichloroethane was added to bring the total volume to 18 ml. This reaction mixture was stirred at room temperature for 2 hours.








To a 16x100 mm reaction tube containing N-BOC-1,5-diaminopentane (33 mg, 0.164 mmol) was added Solution A (2 ml, 0.073 mmol of Example 60 Part D compound). The reaction tube was capped and warmed to 40°C for 20 hours. The reaction was cooled to room temperature and was then passed through an SCX cartridge (CUBCX12M6). The SCX cartridge was washed with methanol (8 ml) and the eluent was collected. Solvents were removed using a speed vac and the resulting residue was taken up in 30% TFA/dichloroethane (2 ml). After agitating the TFA/dichloroethane solution for 2 hours at room temperature, solvents were removed using a speed vac to afford 19 mg (46%) of title compound. MS:  $m/z$  451.21  $(M+H)^+$ .

30

Examples 4 to 103


The following compounds were prepared employing procedures as described in previous Examples.

5

Example No	Structure	Mass Spec. m/z (M+H) <sup>+</sup>
4		466
5		485
6		471
7		485
8		477
9		557
10		454




11




471

12




503

13




507

14




495

15




484

16




468

17




482

18




583

19




425

20




485

21




506

22




501

23




477

24




551

25




475

26




451

27




465

28




466

29




499

30




497

31




511

32




501

33




481

34




487

35




555

36




495

37




451

38




465


471




478




596




435




494



446




45




487

46




473

47




477

48




437

49




487

50




425

51




489

52




485

53




489

54




540

55




499

56




471

57




559

58




482

59




508

60




471

61



461


62



511




63




544

64




497

65




522

66




514

67




475

68




485

69




466

70




453

71




463

72




501

73




489

74




490

75




439

76




465

77




439

78




423

79




477

80




477

81




453

82




415

83




429

84




581

85




411

86




410

87




451

88




464

89




455

90




501

91




425

92




429

93




439

94




452

95




502

96




423

97




429

98




439

99




473

100




452

101




463

102



522


103



501





1. A compound having the formula



and a pharmaceutically acceptable salt thereof and all  
5 stereoisomers thereof, and prodrug esters thereof,  
wherein

at least one of R<sup>1</sup> and R<sup>2</sup> is hydrogen and the other  
of R<sup>1</sup> and R<sup>2</sup> is selected from hydrogen, alkyl, alkenyl,  
alkynyl, aryl, aminoalkylaryl, aminocycloalkylalkyl,  
10 aminoalkyl, aminoalkylcycloalkyl, heteroaryl, arylalkyl,  
heteroarylalkyl, cycloalkyl, cycloalkylalkyl,  
polycycloalkyl, polycycloalkylalkyl, cycloalkenyl,  
cycloheteroalkyl, cycloalkenylalkyl, polycycloalkenyl, or  
polycycloalkenylalkyl; all optionally substituted through  
15 available carbon atoms with 1, 2, 3 or 4 groups selected  
from hydrogen, halo, alkyl, haloalkyl, alkoxy,  
haloalkoxy, alkenyl, alkynyl, cycloalkyl,  
cycloalkylalkyl, cycloheteroalkyl, cycloheteroalkylalkyl,  
aryl, heteroaryl, arylalkyl, arylcycloalkyl, arylalkenyl,  
20 arylalkynyl, aryloxy, aryloxyalkyl, arylalkoxy, arylazo,  
heteroarylalkyl, heteroarylalkenyl, heteroaryloxy,  
hydroxy, nitro, cyano, amino, substituted amino,  
alkylamino, dialkylamino, thiol, alkylthio, arylthio,  
heteroarylthio, arylthioalkyl, aminoalkyl,  
25 alkylloxycarbonylaminoalkyl, arylalkylloxycarbonyl-  
aminoalkyl, alkylcarbonyl, arylcarbonyl,  
arylaminocarbonyl, aminocarbonyl, alkynylaminocarbonyl,  
alkylaminocarbonyl, alkenylaminocarbonyl,  
alkylcarbonyloxy, arylcarbonyloxy, alkylcarbonylamino,  
30 arylcarbonylamino, arylsulfinyl, arylsulfinylalkyl,  
arylsulfonyl, alkylsulfonyl, arylsulfonylamino,  
heteroarylcarbonylamino, heteroarylsulfinyl,  
heteroarylthio, heteroarylsulfonyl, or alkylsulfinyl;



$R^3$  is selected from alkyl, alkenyl, alkynyl, aryl, heteroaryl, arylalkyl, heteroarylalkyl, cycloalkyl, cycloalkylalkyl, polycycloalkyl, polycycloalkylalkyl, cycloalkenyl, cycloheteroalkyl, cycloalkenylalkyl, polycycloalkenyl, or polycycloalkenylalkyl; all optionally substituted through available carbon atoms with 1, 2, 3 or 4 groups selected from hydrogen, halo, alkyl, haloalkyl, alkoxy, haloalkoxy, alkenyl, alkynyl, cycloalkyl, cycloalkylalkyl, cycloheteroalkyl, cycloheteroalkylalkyl, aryl, heteroaryl, arylalkyl, arylcycloalkyl, arylalkenyl, arylalkynyl, aryloxy, aryloxyalkyl, arylalkoxy, arylazo, heteroaryloxy, heteroarylalkyl, heteroarylalkenyl, heteroaryloxy, hydroxy, nitro, cyano, amino, substituted amino, alkylamino, dialkylamino, thiol, alkylthio, arylthio, heteroarylthio, arylthioalkyl, alkylcarbonyl, arylcarbonyl, arylaminocarbonyl, alkoxycarbonyl, aminocarbonyl, alkynylaminocarbonyl, alkylaminocarbonyl, alkenylaminocarbonyl, alkylcarbonyloxy, arylcarbonyloxy, alkylcarbonylamino, arylcarbonylamino, arylsulfinyl, arylsulfinylalkyl, arylsulfonyl, alkylsulfonyl, arylsulfonylamino, heteroarylsulfonylamino, heteroarylsulfinyl, heteroarylthio, heteroarylsulfonyl, or alkylsulfinyl;


$R^5$  and  $R^6$  are the same or different and are independently selected from alkyl, alkenyl, alkynyl, aryl, heteroaryl, arylalkyl, heteroarylalkyl, cycloalkyl, cycloalkylalkyl, polycycloalkyl, polycycloalkylalkyl, cycloalkenyl, cycloheteroalkyl, cycloalkenylalkyl, polycycloalkenyl, polycycloalkenylalkyl, arylcarbonyl, alkylcarbonyl, alkoxycarbonyl, aryloxy, arylsulfonyl, or alkylsulfonyl, or  $R^5$  and  $R^6$  can be taken with the

nitrogen to which they are attached to form a cycloheteroalkyl ring; all optionally substituted through available carbon atoms with 1, 2, 3 or 4 groups selected from hydrogen, halo, alkyl, haloalkyl, alkoxy, haloalkoxy, alkenyl, alkynyl, cycloalkyl, cycloalkylalkyl, cycloheteroalkyl, cycloheteroalkylalkyl, aryl, heteroaryl, arylalkyl, arylcycloalkyl, arylalkenyl, arylalkynyl, aryloxy, aryloxyalkyl, arylalkoxy, arylazo, heteroaryloxo, heteroarylalkyl, heteroarylalkenyl, heteroaryloxy, hydroxy, nitro, cyano, amino, substituted amino, alkylamino, dialkylamino, thiol, alkylthio, arylthio, heteroarylthio, arylthioalkyl, alkylcarbonyl, arylcarbonyl, arylaminocarbonyl, alkoxycarbonyl, aminocarbonyl, alkynylaminocarbonyl, alkylaminocarbonyl, alkenylaminocarbonyl, alkylcarbonyloxy, arylcarbonyloxy, alkylcarbonylamino, arylcarbonylamino, arylsulfinyl, arylsulfinylalkyl, arylsulfonyl, alkylsulfonyl, arylsulfonylamino, heteroarylcarbonylamino, heteroarylsulfinyl, heteroarylthio, heteroarylsulfonyl, or alkylsulfinyl;

R<sup>7</sup> and R<sup>8</sup> are the same or different and are independently selected from alkyl, alkenyl, alkynyl, aryl, heteroaryl, arylalkyl, heteroarylalkyl, cycloalkyl, cycloalkylalkyl, polycycloalkyl, polycycloalkylalkyl, cycloalkenyl, cycloheteroalkyl, cycloalkenylalkyl, polycycloalkenyl, polycycloalkenylalkyl, all optionally substituted through available carbon atoms with 1, 2, 3 or 4 groups selected from hydrogen, halo, alkyl, haloalkyl, alkoxy, haloalkoxy, alkenyl, alkynyl, cycloalkyl, cycloalkylalkyl, cycloheteroalkyl, cycloheteroalkylalkyl, aryl, heteroaryl, arylalkyl, arylcycloalkyl, arylalkenyl, arylalkynyl, aryloxy, aryloxyalkyl, arylalkoxy, arylazo, heteroaryloxo, heteroarylalkyl, heteroarylalkenyl, heteroaryloxy, hydroxy, nitro, cyano, amino, substituted amino, alkylamino, dialkylamino, thiol, alkylthio, arylthio, heteroarylthio, arylthioalkyl, alkylcarbonyl,

arylcarbonyl, arylaminocarbonyl, alkoxycarbonyl,  
 aminocarbonyl, alkynylaminocarbonyl, alkylaminocarbonyl,  
 alkenylaminocarbonyl, alkylcarbonyloxy, arylcarbonyloxy,  
 alkylcarbonylamino, arylcarbonylamino, arylsulfinyl,  
 5 arylsulfinylalkyl, arylsulfonyl, alkylsulfonyl,  
 arylsulfonylamino, heteroarylcarbonylamino,  
 heteroarylsulfinyl, heteroarylthio, heteroarylsulfonyl,  
 or alkylsulfinyl.


10 2. The compound as defined in Claim 1 where  
 (1)




and  $R^1$  and  $R^2$  are independently cycloalkyl, alkenyl,  
 phenyl, benzyl, cyanoalkyl, alkoxycarbonylalkyl, or  
 15 phenyl mono- or disubstituted with lower alkyl, cyano,  
 hydroxy, dialkylamino, alkoxy, benzyloxy, alkylamino,  
 alkoxycarbonyl, pyrrolidino, morpholino, halogen, alkyl  
 substituted with one or more fluorines, then Y is S; and

(2) where X is  $\begin{array}{c} R^4-C \\ || \\ O \end{array}$  and  $R^4$  is  $R^8$ , then  $R^8$  is  
 20 other than alkyl substituted with hydroxyaminocarbonyl.


3. The compound as defined in Claim 1 having the  
 formula




25 4. The compound as defined in Claim 1 having the  
 formula



5. The compound as defined in Claim 1 having the formula




5 6. The compound as defined in Claim 1 having the formula




10 7. The compound as defined in Claim 6 wherein one of R<sup>1</sup> and R<sup>2</sup> is hydrogen and the other is aminoalkylaryl or aminocycloalkylalkyl, and y is 0.


15 8. The compound as defined in Claim 7 wherein one of R<sup>1</sup> and R<sup>2</sup> is




and Y is O.

20 9. The compound as defined in Claim 1 having the structure





10. A compound having the structure



- 5            wherein  $R^1$  and  $R^2$  are the same or different and are independently selected from hydrogen, alkynyl, heteroaryl, aminoalkylaryl, aminocycloalkylalkyl, aminoalkyl, aminoalkylcycloalkyl, heteroarylalkyl, cycloalkenyl, cycloheteroalkyl, heteroaryloxy,
- 10 cycloalkenylalkyl, polycycloalkenyl, polycycloalkenyl-alkyl, or  $R^1$  and  $R^2$  can be taken with the nitrogen to which they are attached to form a cycloheteroalkyl ring; all optionally substituted through available carbon atoms with 1, 2, 3 or 4 groups selected from hydrogen, halo,
- 15 alkyl, haloalkyl, alkoxy, haloalkoxy, alkenyl, alkynyl, cycloalkyl, cycloalkylalkyl, cycloheteroalkyl, cycloheteroalkylalkyl, aryl, heteroaryl, arylalkyl, arylcycloalkyl, arylalkenyl, arylalkynyl, aryloxy, aryloxyalkyl, arylalkoxy, arylazo, heteroaryloxy,
- 20 heteroarylalkyl, heteroarylalkenyl, heteroaryloxy, hydroxy, nitro, cyano, amino, substituted amino, alkylamino, dialkylamino, thiol, alkylthio, arylthio, heteroarylthio, arylthioalkyl, aminoalkyl, alkyloxycarbonylaminoalkyl, arylalkyloxycarbonyl-
- 25 aminoalkyl, alkylcarbonyl, arylcarbonyl, arylaminocarbonyl, alkoxy carbonyl, aminocarbonyl, alkynylaminocarbonyl, alkylaminocarbonyl, alkenylaminocarbonyl, alkylcarbonyloxy, arylcarbonyloxy,

alkylcarbonylamino, arylcarbonylamino, arylsulfinyl,  
arylsulfinylalkyl, arylsulfonyl, alkylsulfonyl,  
arylsulfonylamino, heteroarylcarbonylamino,  
heteroarylsulfinyl, heteroarylthio, heteroarylsulfonyl,  
5 alkylsulfinyl; or a pharmaceutically acceptable salt  
thereof, with the proviso that at least one of R<sup>1</sup> and R<sup>2</sup>  
is hydrogen.

11. A pharmaceutical composition comprising a  
10 compound as defined in Claim 1 and a pharmaceutically  
acceptable carrier therefor.

12. Use of a compound as defined in Claim 1 for  
the preparation of a pharmaceutical composition for  
15 inhibiting a serine protease, for treating and/or  
preventing inflammation, asthma, or allergic rhinitis,  
for treating and/or preventing medical conditions in a  
mammalian species related to tryptase, for treating  
and/or preventing inflammatory bowel disease, psoriasis,  
20 conjunctivitis, atopic dermatitis, rheumatoid arthritis,  
osteoarthritis, chronic inflammatory joint disease,  
diseases of joint cartilage destruction, treating and/or  
preventing myocardial infarction, stroke, angina,  
diabetic retinopathy, diseases involving angiogenesis,  
25 tumor growth, cancer, fibrosis, scleroderma, pulmonary  
fibrosis, liver cirrhosis, myocardial fibrosis,  
neurofibromas and/or hypertrophic scars.

13. A pharmaceutical combination comprising a  
30 compound as defined in Claim 1 in combination with a  
hypolipidemic agent, a  $\beta$ -adrenergic agonist, an  
anticholinergic, an anti-inflammatory corticosteroid or  
an anti-inflammatory agent.

14. The pharmaceutical combination as defined in Claim 13 wherein the  $\beta$ -adrenergic agonist is albuterol, terbutaline, formoterol, fenoterol, salmeterol, bitolterol, or pilbuterol, and the anti-inflammatory agent is beclomethasone, triamcinolone, flurisolide, dexamethasone, budesonide, fluticasone, cromolyn, nedocromil, theophylline, zileuton, zafirleukast, monteleukast and pranleukast, and wherein the hypolipodemic agent is pravastatin, simvastatin, atorvastatin, fluvastatin, cerivastatin, rosuvastatin or itavastatin.



(19) World Intellectual Property Organization  
International Bureau



(43) International Publication Date  
14 February 2002 (14.02.2002)

PCT

(10) International Publication Number  
WO 02/012196 A3

- (51) International Patent Classification<sup>7</sup>: C07K 5/078, A61K 38/55, A61P 7/02
- (74) Agents: DAVIS, Stephen, B. et al.; Bristol-Myers Squibb Company, P.O. Box 4000, Princeton, NJ 08543-4000 (US).
- (21) International Application Number: PCT/US01/22829
- (22) International Filing Date: 20 July 2001 (20.07.2001)
- (25) Filing Language: English
- (26) Publication Language: English
- (30) Priority Data:  
09/633,751 — 7-August 2000 (07-08-2000) — US
- (71) Applicant (for all designated States except US): BRISTOL-MYERS SQUIBB COMPANY [US/US]; P.O. Box 4000, Route 206 and Provinceline Road, Princeton, NJ 08543-4000 (US).
- (72) Inventors; and
- (75) Inventors/Applicants (for US only): BISACCHI, Gregory, S. [US/US]; 130 Mountain Road, Ringoes, NJ 08551 (US). SEILER, Steven, M. [US/US]; 101 North Main Street, Pennington, NJ 08534 (US). LAWRENCE, R., Michael [US/US]; 48 W. Crown Terrace, Yardley, PA 19067 (US). SUTTON, James, C., Jr. [US/US]; 8 Stonelea Drive, Princeton Junction, NJ 08550 (US). SLUSARCHYK, William, A. [US/US]; 19 Richmond Drive, Skillman, NJ 08558 (US). ZHAO, Guohua [US/US]; 56 York Drive, Princeton, NJ 08540 (US).
- (81) Designated States (national): AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZW.
- (84) Designated States (regional): ARIPO patent (GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZW), Eurasian patent (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European patent (AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR), OAPI patent (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG).
- Published:  
— with international search report
- (88) Date of publication of the international search report:  
16 January 2003
- For two-letter codes and other abbreviations, refer to the "Guidance Notes on Codes and Abbreviations" appearing at the beginning of each regular issue of the PCT Gazette.



WO 02/012196 A3

(54) Title: LACTAM COMPOUNDS AND THEIR USE AS INHIBITORS OF SERINE PROTEASES AND METHOD

(57) Abstract: Lactam inhibitors are provided which have the structure (I), x is (a) or (b) wherein Y is O or S and R<sup>4</sup> is (i), (ii) or R<sup>8</sup> at least one of R<sup>1</sup> and R<sup>2</sup> is hydrogen, and R<sup>1</sup>, R<sup>2</sup>, R<sup>3</sup>, R<sup>5</sup>, R<sup>6</sup>, R<sup>7</sup>, and R<sup>8</sup>, are as defined herein. These compounds are inhibitors of tryptase and thus are useful in treating asthma. Methods for treating asthma and related diseases are also provided.

## INTERNATIONAL SEARCH REPORT

Intel Application No

PC 01/22829

A. CLASSIFICATION OF SUBJECT MATTER  
IPC 7 C07K5/078 A61K38/55 A61P7/02

According to International Patent Classification (IPC) or to both national classification and IPC

## B. FIELDS SEARCHED

Minimum documentation searched (classification system followed by classification symbols)  
IPC 7 C07K A61K

Documentation searched other than minimum documentation to the extent that such documents are included in the fields searched

Electronic data base consulted during the international search (name of data base and, where practical, search terms used)

EPO-Internal, BIOSIS, WPI Data, PAJ, CHEM ABS Data

## C. DOCUMENTS CONSIDERED TO BE RELEVANT

Category *	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
P,X	WO 00 47563 A (BRISTOL MYERS SQUIBB CO) 17 August 2000 (2000-08-17) the whole document	1-12
E	WO 01 79261 A (CORVAS INT INC ;ARALDI GIAN LUCA (US); SEMPLE JOSEPH EDWARD (US)) 25 October 2001 (2001-10-25) page 222 -page 223; claims; examples 24,35,48,49,65,66	1,3,11, 12
X	WO 98 50420 A (AKZO NOBEL NV ;ADANG ANTON EGBERT PETER (NL)) 12 November 1998 (1998-11-12) claims; examples	1,3,11, 12
	--- -/--	

☒ Further documents are listed in the continuation of box C.

☒ Patent family members are listed in annex.

## \* Special categories of cited documents :

- \*A\* document defining the general state of the art which is not considered to be of particular relevance
- \*E\* earlier document but published on or after the international filing date
- \*L\* document which may throw doubts on priority claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified)
- \*O\* document referring to an oral disclosure, use, exhibition or other means
- \*P\* document published prior to the international filing date but later than the priority date claimed

- \*T\* later document published after the international filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the invention
- \*X\* document of particular relevance; the claimed invention cannot be considered novel or cannot be considered to involve an inventive step when the document is taken alone
- \*Y\* document of particular relevance; the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled in the art.
- \*G\* document member of the same patent family

Date of the actual completion of the international search

17 June 2002

Date of mailing of the international search report

08/07/2002

Name and mailing address of the ISA

European Patent Office, P.B. 5818 Patentlaan 2  
NL - 2280 HV Rijswijk  
Tel. (+31-70) 340-2040, Tx. 31 651 epo nl,  
Fax: (+31-70) 340-3016

Authorized officer

Fuhr, C

## C.(Continuation) DOCUMENTS CONSIDERED TO BE RELEVANT

Category °	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
X	<p>LEVY ODILE E ET. AL: "Potent and selective thrombin inhibitors incorporating the constrained arginine mimic L-3-piperidyl(N-guanidino)alanine at P-1." JOURNAL OF MEDICINAL CHEMISTRY, vol. 39, no. 23, 1996, pages 4527-4530, XP002202362  ISSN: 0022-2623  see compounds 3 and 6a on page 4527</p>	1,3,11,12
A	<p>WO 95 35313 A (NUTT RUTH F ;CORVAS INT INC (US); LEVY ODILE E (US); RIPKA WILLIAM)  28 December 1995 (1995-12-28)  claims; examples</p>	1-12

## INTERNATIONAL SEARCH REPORT

Information on patent family members

International Application No

PCT/US 01/22829

Patent document cited in search report		Publication date	Patent family member(s)	Publication date
WO 0047563	A	17-08-2000	AU 2630000 A	29-08-2000
			EP 1175405 A1	30-01-2002
			WO 0047563 A1	17-08-2000
			US 6344450 B1	05-02-2002
WO 0179261	A	25-10-2001	AU 5540801 A	30-10-2001
			WO 0179261 A1	25-10-2001
WO 9850420	A	12-11-1998	AU 729910 B2	15-02-2001
			AU 7652098 A	27-11-1998
			BR 9809342 A	04-07-2000
			CN 1254345 T	24-05-2000
			WO 9850420 A1	12-11-1998
			EP 0979240 A1	16-02-2000
			HU 0002942 A2	29-01-2001
			JP 2001524117 T	27-11-2001
			NO 995316 A	01-11-1999
			NZ 500620 A	27-10-2000
			PL 336589 A1	03-07-2000
			TR 9902692 T2	21-07-2000
			ZA 9803629 A	04-11-1998
WO 9535313	A	28-12-1995	US 5714499 A	03-02-1998
			US 5932733 A	03-08-1999
			AT 176241 T	15-02-1999
			AU 2905495 A	15-01-1996
			CA 2192211 A1	28-12-1995
			DE 69507614 D1	11-03-1999
			EP 0765339 A1	02-04-1997
			JP 10503177 T	24-03-1998
			WO 9535313 A1	28-12-1995
			AU 700808 B2	14-01-1999
			AU 2863095 A	15-01-1996
			BR 9508048 A	18-11-1997
			CA 2192210 A1	28-12-1995
			CN 1151166 A	04-06-1997
			EP 0802923 A1	29-10-1997
			JP 10503176 T	24-03-1998
			NO 965353 A	17-02-1997
			NZ 288940 A	28-01-1999
			WO 9535311 A1	28-12-1995
			US 5703208 A	30-12-1997
			US 6034215 A	07-03-2000